Dosing & Uses
Dosage Forms & Strengths
- 50 units/mL (Vaqta adult dose)
- 1440 ELISA units/mL (Havrix adult dose)
Hepatitis A Immunization
Indicated as active immunization against hepatitis A virus (HAV) for any person seeking protection, and persons with the following risks: men who have sex with men, IV or non-IV illicit drug abusers, chronic liver disease, international travelers, close contact with an international adoptee, persons working with HAV-infected primates or HAV in lab setting
2-dose vaccination series: 1 mL IM; separate the 2 doses by 6-18 months (ACIP guidelines); Havrix labeling states separating the dose by 6-12 months
Up-to-date vaccination schedules available at http://www.cdc.gov/vaccines/default.htm
Dosage Forms & Strengths
- 25 units/0.5 mL (Vaqta pediatric dose)
- 720 ELISA units/0.5mL (Havrix pediatric dose)
Hepatitis A Immunization
Indicated as routine vaccination for children at least 12 months of age (ACIP guidelines)
<12 months: Not indicated
Routine vaccination (2-dose series): 0.5 mL IM initiated at aged 12 through 23 months; separate the 2 doses by 6-18 months (ACIP guidelines); Havrix labeling states separating the dose by 6-12 months
Children who have received 1 dose before age 24 months, should receive a second dose 6-18 months after the first dose
Catch up schedule
- For any person ≥2 yr who has not already received hepatitis A vaccine series, give 2 doses separated by 6-18 months if immunity against hepatitis A virus infection is desired
- Minimum interval between the 2-dose series is 6 months
Serious - Use Alternative
Significant - Monitor Closely
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
Injection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%)
Fever > 100.4 F (9-11%)
Otitis media (8%)
Fever > 102 F (3%)
First dose at least 2 wk before exposure to HAV
Current exposure to HAV: may co-administer IG
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not established
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Attenuated strain of hepatitis A virus (HAV) which stimulates active immunity
Onset: 4 wk
These products convey active immunity via stimulation of production of endogenously produced antibodies
The onset of protection from disease is relatively slow, but duration is long lasting (years)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs